Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase
This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon's capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV). In this retrospective observational study, untreated patient...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e59481-e59481 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e59481 |
|---|---|
| container_issue | 5 |
| container_start_page | e59481 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 16 |
| creator | Yoshikawa, Yuji Sakaki, Yu Shinoda, Kei Kataoka, Keiko |
| description | This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon's capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV).
In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital's Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management. |
| doi_str_mv | 10.7759/cureus.59481 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11145932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3073873549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-e46b9da4bb46dc25581207a59f2dd50d8daf7e9214a1fafb2f9c297c839b5d13</originalsourceid><addsrcrecordid>eNpdkkFv1DAQhSMEolXpjTOyxAEOpNhxsrFPqIQClVaiUldwjCb2uPEqsRc7Xmn5hfwsst1SLZz8rPn07Hl6WfaS0Yu6ruR7lQKmeFHJUrAn2WnBFiIXTJRPj_RJdh7jmlLKaF3Qmj7PTrgQvGBleZr9vgWD046A0-TKGFST3aLDGIk35NpNAbZ2CggD-Rj8kJT9lUbo5sl6j3pHrCONHzvr4P76w049uU1dvkLn3ZtIGtjENCBZBQujss4P3iG5VDh5ZzUeORkfyI0fdhtv9fxe0_twUN8hqjT4DUz9jnxKwbo7MvVIlh70Xt_0EPFF9szAEPH84TzLVp-vVs3XfPnty3VzucwVp3TKsVx0UkPZdeVCq6KqBJszgUqaQuuKaqHB1CjncIAZMF1hpCpkrQSXXaUZP8s-HGw3qRtRK9xHNLSbYEcIu9aDbf-dONu3d37bMsbKSvJidnj74BD8z4RxakcbFQ4DOPQptpwuykpwKsWMvv4PXfsU3LzeTNVc1Lwq5Uy9O1Aq-BgDmsffMNruW9IeWtLet2TGXx1v8Aj_7QT_A0xgv44</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073873549</pqid></control><display><type>article</type><title>Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Yoshikawa, Yuji ; Sakaki, Yu ; Shinoda, Kei ; Kataoka, Keiko</creator><creatorcontrib>Yoshikawa, Yuji ; Sakaki, Yu ; Shinoda, Kei ; Kataoka, Keiko</creatorcontrib><description>This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon's capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV).
In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital's Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.59481</identifier><identifier>PMID: 38832144</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Cataracts ; Drug dosages ; Hemorrhage ; Inflammation ; Medical imaging ; Medical records ; Monoclonal antibodies ; Ophthalmology ; Polyps ; Software ; Tomography ; Vascular occlusion ; Visual acuity ; Visual impairment</subject><ispartof>Curēus (Palo Alto, CA), 2024-05, Vol.16 (5), p.e59481-e59481</ispartof><rights>Copyright © 2024, Yoshikawa et al.</rights><rights>Copyright © 2024, Yoshikawa et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Yoshikawa et al. 2024 Yoshikawa et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-e46b9da4bb46dc25581207a59f2dd50d8daf7e9214a1fafb2f9c297c839b5d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145932/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145932/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38832144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshikawa, Yuji</creatorcontrib><creatorcontrib>Sakaki, Yu</creatorcontrib><creatorcontrib>Shinoda, Kei</creatorcontrib><creatorcontrib>Kataoka, Keiko</creatorcontrib><title>Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon's capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV).
In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital's Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management.</description><subject>Cataracts</subject><subject>Drug dosages</subject><subject>Hemorrhage</subject><subject>Inflammation</subject><subject>Medical imaging</subject><subject>Medical records</subject><subject>Monoclonal antibodies</subject><subject>Ophthalmology</subject><subject>Polyps</subject><subject>Software</subject><subject>Tomography</subject><subject>Vascular occlusion</subject><subject>Visual acuity</subject><subject>Visual impairment</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkkFv1DAQhSMEolXpjTOyxAEOpNhxsrFPqIQClVaiUldwjCb2uPEqsRc7Xmn5hfwsst1SLZz8rPn07Hl6WfaS0Yu6ruR7lQKmeFHJUrAn2WnBFiIXTJRPj_RJdh7jmlLKaF3Qmj7PTrgQvGBleZr9vgWD046A0-TKGFST3aLDGIk35NpNAbZ2CggD-Rj8kJT9lUbo5sl6j3pHrCONHzvr4P76w049uU1dvkLn3ZtIGtjENCBZBQujss4P3iG5VDh5ZzUeORkfyI0fdhtv9fxe0_twUN8hqjT4DUz9jnxKwbo7MvVIlh70Xt_0EPFF9szAEPH84TzLVp-vVs3XfPnty3VzucwVp3TKsVx0UkPZdeVCq6KqBJszgUqaQuuKaqHB1CjncIAZMF1hpCpkrQSXXaUZP8s-HGw3qRtRK9xHNLSbYEcIu9aDbf-dONu3d37bMsbKSvJidnj74BD8z4RxakcbFQ4DOPQptpwuykpwKsWMvv4PXfsU3LzeTNVc1Lwq5Uy9O1Aq-BgDmsffMNruW9IeWtLet2TGXx1v8Aj_7QT_A0xgv44</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Yoshikawa, Yuji</creator><creator>Sakaki, Yu</creator><creator>Shinoda, Kei</creator><creator>Kataoka, Keiko</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240501</creationdate><title>Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase</title><author>Yoshikawa, Yuji ; Sakaki, Yu ; Shinoda, Kei ; Kataoka, Keiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-e46b9da4bb46dc25581207a59f2dd50d8daf7e9214a1fafb2f9c297c839b5d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cataracts</topic><topic>Drug dosages</topic><topic>Hemorrhage</topic><topic>Inflammation</topic><topic>Medical imaging</topic><topic>Medical records</topic><topic>Monoclonal antibodies</topic><topic>Ophthalmology</topic><topic>Polyps</topic><topic>Software</topic><topic>Tomography</topic><topic>Vascular occlusion</topic><topic>Visual acuity</topic><topic>Visual impairment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshikawa, Yuji</creatorcontrib><creatorcontrib>Sakaki, Yu</creatorcontrib><creatorcontrib>Shinoda, Kei</creatorcontrib><creatorcontrib>Kataoka, Keiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshikawa, Yuji</au><au>Sakaki, Yu</au><au>Shinoda, Kei</au><au>Kataoka, Keiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>e59481</spage><epage>e59481</epage><pages>e59481-e59481</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon's capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV).
In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital's Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38832144</pmid><doi>10.7759/cureus.59481</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2024-05, Vol.16 (5), p.e59481-e59481 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11145932 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Cataracts Drug dosages Hemorrhage Inflammation Medical imaging Medical records Monoclonal antibodies Ophthalmology Polyps Software Tomography Vascular occlusion Visual acuity Visual impairment |
| title | Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Effectiveness%20of%20Intravitreal%20Brolucizumab%20Injection%20in%20Combination%20With%20Sub-Tenon's%20Capsule%20Triamcinolone%20Acetonide%20Injection%20for%20Polypoidal%20Choroidal%20Vasculopathy%20During%20the%20Loading%20Phase&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Yoshikawa,%20Yuji&rft.date=2024-05-01&rft.volume=16&rft.issue=5&rft.spage=e59481&rft.epage=e59481&rft.pages=e59481-e59481&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.59481&rft_dat=%3Cproquest_pubme%3E3073873549%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3073873549&rft_id=info:pmid/38832144&rfr_iscdi=true |